Company intelligence / Profile preview

vVARDIS

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

vVARDIS has developed a patented, biomimetic technology that enables the regeneration of tooth enamel, offering a non-invasive, drill-free solution for early tooth decay. Their Curodont product line is used by thousands of dental clinics globally and has treated over 300,000 teeth as of 2024. The technology is recognized as a new standard of care in lectures at leading universities in the US and Europe.

Therapeutic areas: Other
Modalities: Device (for professional dental application)Biomimetic compound-based therapy (enamel regeneration)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Curodont

Commercial

Indications: Early tooth decay, Dental caries

Partnerships

OrbiMed (strategic investor/partner)CareQuest Innovation PartnersBluemercury retail partnership for US distribution

Beyond the preview

Go deeper on vVARDIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vVARDIS.